Immunologic derangement preceding clinical autoimmunity

• Published in: Lupus Vol. 23; no. 12; pp. 1305 - 1308
• Main Authors: Dellavance, A, Coelho Andrade, LE
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-10-2014; Sage Publications Ltd
• Subjects: Antibodies; Autoantibodies - blood; Autoimmune diseases; Autoimmune Diseases - immunology; Autoimmunity; Biomarkers; Disease; Humans; Immunoglobulins; Immunology; Laboratories; Lupus; Mitochondria; Mitochondria - immunology; Brazil; Autoimmunity; autoimmune diseases; mechanisms of disease; autoantibodies; immunological tolerance
• ISSN: 0961-2033; 1477-0962
• DOI: 10.1177/0961203314531346

Autoantibodies are valuable markers for the recognition of autoimmune diseases. Over the last 25 years, several investigators have consistently shown that autoantibodies precede the clinical onset of cognate diseases by years or decades. This phenomenon, regularly observed in the natural history of autoimmune diseases, indicates that autoimmunity develops through successive stages across a variable period of time until the characteristic manifestations of disease are clinically apparent. Recent evidence indicates that the pre-clinical stages of autoimmune diseases involve a series of immunologic derangements and that this process is dynamic and progressive. During the years preceding clinical disease onset, there is progressive intensification in the humoral autoimmune response, characterized by increases in autoantibody titer, avidity, number of immunoglobulin isotypes, and spread of epitopes and of autoantigens targeted. This scenario is reminiscent of cancer processes that develop slowly by means of progressive stages, and may be interrupted by early detection and therapeutic intervention. Therefore, it might be reasoned that early intervention may be more effective in reverting the less firmly established autoimmune abnormalities at the pre-clinical stage of autoimmunity. With the continuous progress in novel immunologic therapeutic strategies, one can envision the possibility that early intervention at pre-clinical stages may lead to prevention of overt disease development and even cure of the autoimmune disorder.